tiprankstipranks
Trending News
More News >
United Therapeutics (UTHR)
NASDAQ:UTHR

United Therapeutics (UTHR) AI Stock Analysis

Compare
590 Followers

Top Page

UT

United Therapeutics

(NASDAQ:UTHR)

Rating:76Outperform
Price Target:
$318.00
▲(9.31%Upside)
United Therapeutics' strong financial performance and positive earnings call outlook are significant strengths, contributing to a high overall score. The stock's attractive valuation further supports its potential, despite mixed technical indicators.
Positive Factors
Financial Performance
United Therapeutics has multiple consecutive quarters of double-digit revenue growth and strong Tyvaso franchise momentum.
Organ Platform Development
The first-ever human clinical trial of a manufactured organ alternative highlights UTHR’s first-mover advantage.
Tyvaso Expansion
UTHR is well equipped to exploit the potential first-mover advantage as a new inhaled therapy for IPF.
Negative Factors
Competitive Pressure
Recent competitor data introduces potential headwinds for the Tyvaso franchise and increases uncertainty into the upcoming TETON readouts.
Market Dynamics
Liquidia's FDA approval of Yutrepia is seen as an incremental negative for United Therapeutics' Tyvaso franchise.

United Therapeutics (UTHR) vs. SPDR S&P 500 ETF (SPY)

United Therapeutics Business Overview & Revenue Model

Company DescriptionUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
How the Company Makes MoneyUnited Therapeutics generates revenue through the sale of its pharmaceutical products, primarily targeting treatments for pulmonary arterial hypertension (PAH) and certain cancers. The company earns money by commercializing its proprietary drugs, such as Remodulin, Tyvaso, and Orenitram, which are sold to healthcare providers and patients worldwide. Additionally, United Therapeutics benefits from government contracts, collaborations, and partnerships that support research and development initiatives. The company also invests in expanding its product line through continuous innovation and clinical trials, which can lead to new approvals and increased market share, further driving revenue growth.

United Therapeutics Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating strategic focus or diversification.
Chart InsightsUnited Therapeutics has demonstrated strong growth in its treprostinil product line, with Tyvaso, Orenitram, Remodulin, and Unituxin achieving consistent double-digit growth for 11 consecutive quarters. This momentum is reflected in the latest earnings, with a record revenue of $794 million, up 17% from the previous year. Despite increased competition in the PAH market, the company remains optimistic about sustaining growth through strategic investments and a robust innovation pipeline, including five registration phase studies and a pending FDA marketing application.
Data provided by:Main Street Data

United Therapeutics Earnings Call Summary

Earnings Call Date:Apr 30, 2025
(Q1-2025)
|
% Change Since: -3.28%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with record revenue growth and strategic investments in pipeline expansion and capital allocation. Despite facing challenges in xenotransplantation and an increasingly competitive landscape, the company remains confident in sustained double-digit growth and product portfolio strength.
Q1-2025 Updates
Positive Updates
Record Revenue Quarter
United Therapeutics reported a record revenue of $794 million for the first quarter of 2025, representing a 17% growth from the same quarter in 2024, marking the 9th record revenue quarter out of the last 12.
Strong Product Portfolio Performance
Double-digit revenue growth was driven by robust results for treprostinil products, including Tyvaso, Orenitram, Remodulin, and Unituxin, with Tyvaso DPI positioned for sustained long-term growth.
Expansion and Capital Allocation
Significant investments in new manufacturing facilities and acquisitions, such as IVIVA and Miromatrix, were made to enhance organ alternative development expertise, alongside a $1 billion share repurchase program.
Positive Regulatory Feedback
Positive FDA feedback on the UTHYMOKIDNEY program allows for IND submissions without additional Baboon clinical studies, advancing the pipeline's registration phase studies and clinical trials.
Negative Updates
Challenges in Xenotransplantation
The UTHYMOKIDNEY program faced challenges as a participant in an EIND study had to be explanted due to an unrelated infection, highlighting the complexities in managing immunosuppression.
Competitive Landscape Concerns
The competitive landscape for pulmonary arterial hypertension (PAH) is intensifying, with emerging competitor dynamics and upcoming data releases that could impact market share.
Company Guidance
During the first quarter of 2025, United Therapeutics Corporation reported a record revenue of $794 million, marking a 17% growth from the same period in 2024. This achievement represents the ninth record revenue quarter out of the past twelve, driven by robust performance across their treprostinil products, including Tyvaso, Orenitram, Remodulin, and Unituxin, which have maintained double-digit growth for 11 consecutive quarters. The company continues to focus on its innovation pipeline, with five registration phase studies underway and a pending marketing application at the FDA, alongside several new preclinical candidates. Despite the increased competition in the PAH market, United Therapeutics remains optimistic about sustaining its growth trajectory due to their strategic capital allocation, strict financial discipline, and strong commercial execution.

United Therapeutics Financial Statement Overview

Summary
United Therapeutics showcases strong financial health with robust revenue growth, high profit margins, and financial stability marked by low leverage and solid cash flow support.
Income Statement
85
Very Positive
United Therapeutics has demonstrated strong financial performance with a consistent increase in total revenue over multiple years. The TTM revenue growth rate is approximately 4.06%, and the gross profit margin stands at a robust 89.00%. Net profit margin is currently 40.43%, indicating efficient cost management and profitability. EBIT and EBITDA margins are also strong, at 46.87% and 52.21% respectively, reflecting solid operational efficiency.
Balance Sheet
80
Positive
The balance sheet is marked by a strong equity position with an equity ratio of 87.89%, indicating a low reliance on debt. The debt-to-equity ratio is low at 0.03, showcasing financial stability. Return on equity is a healthy 17.79%, reflecting effective use of equity capital in generating profits. However, the relatively low total liabilities suggest limited financial leverage.
Cash Flow
78
Positive
The company has demonstrated positive cash flow metrics with a free cash flow growth rate of 4.45%. The operating cash flow to net income ratio is 1.17, indicating strong cash generation relative to net income. The free cash flow to net income ratio is 0.93, showing efficient translation of earnings into free cash flow. The cash flow is stable and supports the company's operational needs.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.99B2.88B2.33B1.94B1.69B1.48B
Gross Profit2.66B2.57B2.07B1.79B1.56B1.38B
EBITDA1.56B1.65B1.39B1.04B736.80M646.30M
Net Income1.21B1.20B984.80M727.30M475.80M514.80M
Balance Sheet
Total Assets4.64B7.36B7.17B6.04B5.17B4.62B
Cash, Cash Equivalents and Short-Term Investments1.73B3.27B2.99B4.15B3.58B2.98B
Total Debt800.00M300.00M700.00M800.00M800.00M800.00M
Total Liabilities1.20B920.00M1.18B1.25B1.21B1.22B
Stockholders Equity3.45B6.44B5.98B4.80B3.96B3.40B
Cash Flow
Free Cash Flow1.13B1.08B747.60M663.70M477.40M696.40M
Operating Cash Flow1.41B1.33B978.00M802.50M598.20M755.70M
Investing Cash Flow-482.80M417.20M-719.60M-811.50M-486.90M-738.50M
Financing Cash Flow-280.60M-1.25B-11.90M75.40M44.80M-16.90M

United Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price290.91
Price Trends
50DMA
300.76
Negative
100DMA
310.41
Negative
200DMA
337.36
Negative
Market Momentum
MACD
-5.38
Positive
RSI
46.07
Neutral
STOCH
44.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTHR, the sentiment is Neutral. The current price of 290.91 is below the 20-day moving average (MA) of 295.81, below the 50-day MA of 300.76, and below the 200-day MA of 337.36, indicating a bearish trend. The MACD of -5.38 indicates Positive momentum. The RSI at 46.07 is Neutral, neither overbought nor oversold. The STOCH value of 44.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UTHR.

United Therapeutics Risk Analysis

United Therapeutics disclosed 33 risk factors in its most recent earnings report. United Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

United Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
84
Outperform
$11.91B20.0030.22%24.49%244.87%
78
Outperform
$12.72B11.6022.69%25.11%46.46%
76
Outperform
$12.82B11.4719.94%19.85%21.16%
74
Outperform
$13.30B212.650.47%17.13%-88.78%
71
Outperform
$10.58B20.409.64%17.99%152.10%
53
Neutral
$15.30B-123.93%-99.70%
51
Neutral
$7.55B0.39-61.90%2.32%17.14%1.55%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
UTHR
United Therapeutics
290.91
-20.13
-6.47%
BMRN
BioMarin Pharmaceutical
56.19
-24.79
-30.61%
EXEL
Exelixis
43.62
21.66
98.63%
INCY
Incyte
68.73
11.07
19.20%
SMMT
Summit Therapeutics
21.20
14.31
207.69%
GMAB
Genmab
20.74
-4.41
-17.53%

United Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
United Therapeutics Shareholders Approve Key Resolutions
Neutral
Jun 27, 2025

On June 26, 2025, United Therapeutics held its Annual Meeting of Shareholders where four key matters were voted on. The shareholders elected directors for a one-year term, approved an advisory resolution on executive compensation, amended the 2015 Stock Incentive Plan, and ratified Ernst & Young LLP as the independent public accounting firm for 2025.

The most recent analyst rating on (UTHR) stock is a Hold with a $319.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.

Private Placements and Financing
United Therapeutics Secures $2.5 Billion Credit Facility
Neutral
Apr 28, 2025

On April 25, 2025, United Therapeutics Corporation entered into a Credit Agreement with Wells Fargo and other lenders, establishing an unsecured revolving credit facility of up to $2.5 billion, with the possibility of increasing by an additional $750 million. The agreement allows for refinancing existing debt and supporting general corporate purposes. Concurrently, the company borrowed $200 million to repay its previous 2022 Credit Agreement, which was terminated without penalties.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 11, 2025